Essa Pharma INC

ESSA Pharma Inc. announced the completion of its acquisition by XenoTherapeutics, with shareholders receiving cash and contingent value rights.

ESSA Pharma Inc. securityholders overwhelmingly approved the acquisition by XenoTherapeutics Inc. via a statutory plan of arrangement.

ESSA Pharma Inc. announced a class action lawsuit was filed against it on September 30, 2025, alleging breach of contract and promissory estoppel related to disclosures made in an August 14, 2025 8-K filing.

ESSA Pharma Inc. received an amended Interim Order from the Supreme Court of British Columbia, approving key dates for its special meeting and court hearing related to the business combination with XenoTherapeutics Inc.

ESSA Pharma Inc. announced an amendment to its Business Combination Agreement with XenoTherapeutics, reducing the expected cash distribution to shareholders at closing and introducing contingent value rights.

ESSA Pharma Inc. has adjourned its special meeting to approve the acquisition by XenoTherapeutics, Inc. to September 29, 2025, to discuss revised financial terms.

ESSA Pharma Inc. has entered a definitive agreement to be acquired by XenoTherapeutics, Inc., signaling a strategic pivot following the termination of its masofaniten clinical trials.

ESSA Pharma Inc. has terminated its clinical trials for masofaniten (EPI-7386) and initiated a strategic review to maximize shareholder value following disappointing interim results.

ESSA Pharma Inc. has terminated its clinical trials for masofaniten and initiated a strategic review to maximize shareholder value after interim data revealed the drug's ineffectiveness compared to standard treatment.

ESSA Pharma's Q3 2024 report details ongoing clinical trials for its prostate cancer drug, masofaniten, and its financial position.

ESSA Pharma reported its financial results for the quarter ended March 31, 2024, and provided updates on its clinical trials for its prostate cancer drug candidate, masofaniten.

ESSA Pharma's Q1 2024 report details ongoing clinical trials for its prostate cancer drug, masofaniten, and provides a financial overview.

ESSA Pharma Inc. has halted its clinical trials for masofaniten (EPI-7386) and is exploring strategic options to maximize shareholder value.

ESSA Pharma's President and CEO, David Parkinson, reported the disposal of all his common shares as part of the company's acquisition by Xeno Acquisition Corp.

ESSA Pharma Inc.'s Chief Financial Officer, David S. Wood, reported the disposal of 33,343 common shares following a business combination.

ESSA Pharma Inc. director Franklin M. Berger reported the sale of all his common shares following the company's acquisition by Xeno Acquisition Corp. for cash and contingent value rights.

ESSA Pharma Inc. Director Richard Glickman disposed of 43,240 common shares as part of a business combination agreement where the company was acquired for cash and contingent value rights.

ESSA Pharma Director Scott Requadt reported the disposition of 30,002 common shares as part of the company's acquisition by Xeno Acquisition Corp. for cash and contingent value rights.

ESSA Pharma Director John Alexander Martin reported the disposition of all his common shares following the company's acquisition by Xeno Acquisition Corp. for cash and contingent value rights.

ESSA Pharma Inc. is facing a putative class action lawsuit alleging breach of contract and promissory estoppel related to disclosures made prior to its announced business combination with XenoTherapeutics Inc.

ESSA Pharma Inc. announced an amended Interim Order from the Supreme Court of British Columbia, confirming key dates for its Special Meeting and court hearing related to the business combination with XenoTherapeutics Inc.

ESSA Pharma Inc. has amended its business combination agreement, reducing the immediate cash payout to shareholders while increasing the contingent value rights due to a Nasdaq trading issue.

ESSA Pharma Inc. has amended its business combination agreement, increasing the contingent value right component and contingent reserve due to new potential liabilities, while maintaining the expected upfront cash payment.

ESSA Pharma Inc. has amended its business combination agreement with XenoTherapeutics, reducing the upfront cash payment to shareholders and introducing a contingent value right.

ESSA Pharma Inc. has adjourned its special meeting to approve the XenoTherapeutics acquisition, citing ongoing discussions for revised financial terms.

ESSA Pharma Inc. was acquired by Xeno Acquisition Corp. on October 9, 2025, leading to reporting persons ceasing beneficial ownership.

ESSA Pharma Inc. and major shareholder BVF have agreed to waive a beneficial ownership limitation, allowing BVF to fully exercise its common share purchase warrants.

Soleus Capital Master Fund, L.P. has increased its beneficial ownership in ESSA Pharma, Inc. to 9.8% of outstanding common stock after unwinding a cash-settled swap and acquiring 2.1 million shares.

BML Investment Partners, L.P., holding a 9.5% stake in ESSA Pharma Inc., has filed a Schedule 13D advocating for the company's liquidation or sale to return capital to shareholders.

Soleus Capital Master Fund and its affiliates have filed an Amendment No. 1 to Schedule 13D, disclosing a 5.1% beneficial ownership stake in ESSA Pharma, Inc., alongside substantial economic exposure through cash-settled swap transactions.

Soleus Capital, a significant shareholder in ESSA Pharma, Inc., has filed a Schedule 13D to advocate for the company to wind down operations and distribute its cash to shareholders, citing the current share price being significantly below its cash per share.

Tang Capital Management and its affiliated entities have filed an amended Schedule 13G, reporting zero beneficial ownership of ESSA Pharma Inc. common shares.

Tang Capital Management and its affiliated entities have filed an amended Schedule 13G, reporting zero beneficial ownership of ESSA Pharma Inc. common shares.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported reducing their beneficial ownership in ESSA Pharma Inc. to below the 5% threshold.

Tang Capital Management and affiliated entities have amended their SEC filing for ESSA Pharma Inc., indicating a shift from an active to a passive investment strategy, no longer seeking to influence company control.

PFM Health Sciences and its affiliates have reported that they no longer beneficially own any common shares of ESSA Pharma Inc., holding 0% of the outstanding class as of December 31, 2024.

BML Investment Partners, L.P. has filed an amended Schedule 13G to correct its beneficial ownership in ESSA Pharma Inc., reporting a 9.5% stake as of December 31, 2024.